vs

Side-by-side financial comparison of Eversource Energy (ES) and Zoetis (ZTS). Click either name above to swap in a different company.

Eversource Energy is the larger business by last-quarter revenue ($3.4B vs $2.4B, roughly 1.4× Zoetis). Zoetis runs the higher net margin — 25.3% vs 12.6%, a 12.7% gap on every dollar of revenue. On growth, Eversource Energy posted the faster year-over-year revenue change (13.4% vs 3.0%). Zoetis produced more free cash flow last quarter ($732.0M vs $-67.3M). Over the past eight quarters, Zoetis's revenue compounded faster (4.4% CAGR vs 0.6%).

Eversource Energy is a publicly traded, Fortune 500 energy company headquartered in Springfield, Massachusetts with additional corporate offices in Hartford, Connecticut, and Boston, Massachusetts, with several regulated subsidiaries offering retail electricity, natural gas service and water service to approximately 4 million customers in Connecticut, Massachusetts, and New Hampshire.

Zoetis Inc. (/zō-EH-tis/) is an American drug company, the world's largest producer of medicine and vaccinations for pets and livestock. The company was a subsidiary of Pfizer, the world's largest drug maker, but with Pfizer's spinoff of its 83% interest in the firm it is now a completely independent company. The company directly markets its products in approximately 45 countries, and sells them in more than 100 countries. Operations outside the United States accounted for 50% of the total re...

ES vs ZTS — Head-to-Head

Bigger by revenue
ES
ES
1.4× larger
ES
$3.4B
$2.4B
ZTS
Growing faster (revenue YoY)
ES
ES
+10.4% gap
ES
13.4%
3.0%
ZTS
Higher net margin
ZTS
ZTS
12.7% more per $
ZTS
25.3%
12.6%
ES
More free cash flow
ZTS
ZTS
$799.3M more FCF
ZTS
$732.0M
$-67.3M
ES
Faster 2-yr revenue CAGR
ZTS
ZTS
Annualised
ZTS
4.4%
0.6%
ES

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
ES
ES
ZTS
ZTS
Revenue
$3.4B
$2.4B
Net Profit
$423.2M
$603.0M
Gross Margin
70.2%
Operating Margin
21.1%
31.9%
Net Margin
12.6%
25.3%
Revenue YoY
13.4%
3.0%
Net Profit YoY
468.8%
3.8%
EPS (diluted)
$1.11
$1.37

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ES
ES
ZTS
ZTS
Q4 25
$3.4B
$2.4B
Q3 25
$3.2B
$2.4B
Q2 25
$2.8B
$2.5B
Q1 25
$4.1B
$2.2B
Q4 24
$3.0B
$2.3B
Q3 24
$3.1B
$2.4B
Q2 24
$2.5B
$2.4B
Q1 24
$3.3B
$2.2B
Net Profit
ES
ES
ZTS
ZTS
Q4 25
$423.2M
$603.0M
Q3 25
$369.4M
$721.0M
Q2 25
$354.6M
$718.0M
Q1 25
$552.7M
$631.0M
Q4 24
$74.4M
$581.0M
Q3 24
$-116.2M
$682.0M
Q2 24
$337.2M
$624.0M
Q1 24
$523.7M
$599.0M
Gross Margin
ES
ES
ZTS
ZTS
Q4 25
70.2%
Q3 25
71.5%
Q2 25
73.6%
Q1 25
72.0%
Q4 24
69.5%
Q3 24
70.6%
Q2 24
71.7%
Q1 24
70.6%
Operating Margin
ES
ES
ZTS
ZTS
Q4 25
21.1%
31.9%
Q3 25
21.4%
37.0%
Q2 25
23.4%
36.7%
Q1 25
22.5%
36.5%
Q4 24
11.7%
31.6%
Q3 24
20.0%
36.6%
Q2 24
23.8%
33.0%
Q1 24
25.4%
34.1%
Net Margin
ES
ES
ZTS
ZTS
Q4 25
12.6%
25.3%
Q3 25
11.5%
30.0%
Q2 25
12.5%
29.2%
Q1 25
13.4%
28.4%
Q4 24
2.5%
25.1%
Q3 24
-3.8%
28.6%
Q2 24
13.3%
26.4%
Q1 24
15.7%
27.4%
EPS (diluted)
ES
ES
ZTS
ZTS
Q4 25
$1.11
$1.37
Q3 25
$0.99
$1.63
Q2 25
$0.96
$1.61
Q1 25
$1.50
$1.41
Q4 24
$0.16
$1.29
Q3 24
$-0.33
$1.50
Q2 24
$0.95
$1.37
Q1 24
$1.49
$1.31

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ES
ES
ZTS
ZTS
Cash + ST InvestmentsLiquidity on hand
$135.4M
Total DebtLower is stronger
Stockholders' EquityBook value
$16.2B
$3.3B
Total Assets
$63.8B
$15.5B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ES
ES
ZTS
ZTS
Q4 25
$135.4M
Q3 25
$259.3M
$2.1B
Q2 25
$343.7M
$1.4B
Q1 25
$111.4M
$1.7B
Q4 24
$26.7M
$2.0B
Q3 24
$97.9M
$1.7B
Q2 24
$1.6B
Q1 24
$2.0B
Stockholders' Equity
ES
ES
ZTS
ZTS
Q4 25
$16.2B
$3.3B
Q3 25
$16.0B
$5.4B
Q2 25
$15.7B
$5.0B
Q1 25
$15.3B
$4.7B
Q4 24
$15.0B
$4.8B
Q3 24
$15.0B
$5.2B
Q2 24
$14.8B
$5.0B
Q1 24
$14.5B
$5.1B
Total Assets
ES
ES
ZTS
ZTS
Q4 25
$63.8B
$15.5B
Q3 25
$61.7B
$15.2B
Q2 25
$61.0B
$14.5B
Q1 25
$60.2B
$14.1B
Q4 24
$59.6B
$14.2B
Q3 24
$58.6B
$14.4B
Q2 24
$58.4B
$14.2B
Q1 24
$57.3B
$14.3B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ES
ES
ZTS
ZTS
Operating Cash FlowLast quarter
$916.1M
$893.0M
Free Cash FlowOCF − Capex
$-67.3M
$732.0M
FCF MarginFCF / Revenue
-2.0%
30.7%
Capex IntensityCapex / Revenue
29.2%
6.7%
Cash ConversionOCF / Net Profit
2.16×
1.48×
TTM Free Cash FlowTrailing 4 quarters
$-45.1M
$2.3B

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ES
ES
ZTS
ZTS
Q4 25
$916.1M
$893.0M
Q3 25
$1.1B
$938.0M
Q2 25
$1.1B
$486.0M
Q1 25
$1.0B
$587.0M
Q4 24
$642.1M
$905.0M
Q3 24
$555.6M
$951.0M
Q2 24
$670.7M
$502.0M
Q1 24
$291.3M
$595.0M
Free Cash Flow
ES
ES
ZTS
ZTS
Q4 25
$-67.3M
$732.0M
Q3 25
$-26.3M
$805.0M
Q2 25
$15.3M
$308.0M
Q1 25
$33.2M
$438.0M
Q4 24
$-546.5M
$689.0M
Q3 24
$-515.4M
$784.0M
Q2 24
$-400.8M
$370.0M
Q1 24
$-858.1M
$455.0M
FCF Margin
ES
ES
ZTS
ZTS
Q4 25
-2.0%
30.7%
Q3 25
-0.8%
33.5%
Q2 25
0.5%
12.5%
Q1 25
0.8%
19.7%
Q4 24
-18.4%
29.7%
Q3 24
-16.8%
32.8%
Q2 24
-15.8%
15.7%
Q1 24
-25.7%
20.8%
Capex Intensity
ES
ES
ZTS
ZTS
Q4 25
29.2%
6.7%
Q3 25
35.0%
5.5%
Q2 25
36.7%
7.2%
Q1 25
24.5%
6.7%
Q4 24
40.0%
9.3%
Q3 24
35.0%
7.0%
Q2 24
42.3%
5.6%
Q1 24
34.5%
6.4%
Cash Conversion
ES
ES
ZTS
ZTS
Q4 25
2.16×
1.48×
Q3 25
2.98×
1.30×
Q2 25
2.98×
0.68×
Q1 25
1.88×
0.93×
Q4 24
8.63×
1.56×
Q3 24
1.39×
Q2 24
1.99×
0.80×
Q1 24
0.56×
0.99×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ES
ES

Residential$1.2B35%
Commercial$789.0M23%
Eversource Electric Transmission$573.8M17%
Wholesale Transmission Revenue$570.0M17%
Industrial$102.6M3%
Water Distribution Segment$58.4M2%
Eversource Water$56.3M2%
Other Revenue Adjustmentsfrom Contractswith Customers$25.9M1%

ZTS
ZTS

Other$1.3B56%
Livestock$234.0M10%
Pain Sedation$209.0M9%
Other Pharmaceuticals$188.0M8%
Swine$125.0M5%
Poultry$117.0M5%
Fish$81.0M3%
Other Non Pharmaceuticals$70.0M3%
Manufactured Product Other$18.0M1%
Medicated Feed Additives$12.0M1%

Related Comparisons